All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
The clinical impact of microRNA-99a in AML patients undergoing allo-HSCT – a Chinese study
Recent studies have shown that microRNA-99a (miR-99a) is upregulated on leukemia stem cells and is associated with poor prognosis in acute myeloid leukemia (AML) patients.1 However, the clinical significance of miR-99a and its predictive value in AML patients undergoing post-allogeneic hematopoietic stem cell transplantation (allo-HSCT) has not been evaluated yet.2
Zhiheng Cheng from Huaihe Hospital of Henan University, Kaifeng, China, and colleagues retrospectively analyzed 74 de novo AML patients with miR-99a expression who underwent allo-HSCT. Data was collected from The Cancer Genome Atlas database. Median follow-up time was 29 months. Their findings were published ahead of print in Bone Marrow Transplantation on 7 March 2018.
Patients were divided into two groups based on their miR-99a expression levels:
- miR-99ahigh group (miR-99a levels were above or equal to median expression level): n = 37, median age = 51 years (range, 22–65)
- miR-99alow group (miR-99a levels were lower than median expression level): n = 37, median age = 51 years (range, 18–72)
Key findings:
-
Survival in all patients
- Median event-free survival (EFS): 12.8 (range, 1.9–106.9) months
- Median overall survival (OS): 29 (range, 6.6–128.5) months
- Patients in the miR-99ahigh group had significantly shorter EFS (P = 0.026) and OS (P = 0.010) than the miR-99alow group
- High miR-99a expression associated with inferior EFS: HR = 1.834 (95% CI, 1.056–3.160), P = 0.029
- High miR-99a expression associated with inferior OS: HR = 2.012 (95% CI, 1.167–3.467), P = 0.012
- High miR-99a expression was an independent risk factor for EFS: HR = 1.909 (95% CI, 1.043–3.494), P = 0.036
- High miR-99a expression was an independent risk factor for OS: HR = 2.179, (95% CI, 1.192–3.982), P = 0.011
In summary, these results showed that high miR-99a expression may be an efficient marker to predict inferior outcomes in AML patients undergoing allo-HSCT. The authors further added that their findings indicated that “allo-HSCT could not overcome the adverse prognostic effect of miR-99a.” Further studies are required to validate these results.
References